Research and Markets: Amgen Pipeline, Products, Performance and Potential 2010 - Amgen to Open European HQ in UK!

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Amgen: Pipeline, Products, Performance and Potential" company profile to their offering.

Amgen to open European HQ in UK!

Amgen's business is currently strongly focused in the US, with 78.0 per cent of sales being generated in this market, however, the company is endeavouring to expand its operations in foreign markets. In March 2007, Amgen completed a new European headquarters in Uxbridge, UK, which in conjunction with its expanded Cambridge, UK, R&D facilities, will conduct the company's largest ever international clinical trial programme across 31 European countries.

2009 could have been a very strong year for Amgen, however, the performance of Aranesp was a significant let down. Safety issues have led to new usage guidelines for the product and others in its class. In the medium-term, this is expected to lead to further losses. Amgen will be hoping it can overcome these difficulties through its new infrastructure and increasingly expanding product portfolio.

In recent years there has been a significant shift in the make-up of Amgens product portfolio. Five years ago, Epogen and Neupogen accounted for approximately 98 per cent of sales, however in 2009, they now account for 26.9 per cent of sales. Both of these products face challenges due to the loss of patent protection and consequently, Neulasta and Enbrel are forecast to be main growth drivers for Amgen in the short- to medium-term, whilst Aranesp will continue to make strong contributions despite declining sales.

This new strategic report provides a detailed analysis of Amgens competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.

Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Assess the performance of, and risks to, Amgen's leading launched products:

  • When will they come under generic/biosimilar threat?
  • Are sales rising or declining over the next 7 years, and why?
  • Which products are still in research, and for what indications?
  • What are the product life extension possibilities; Combinations? New formulations?
  • Which products are central to the company's commercial health?

Key Topics Covered:

  • Latest Results
  • - Introduction
  • - Current Financial Position
  • - Company Performance
  • - Business Segment Performance
  • - Geographic Segment Performance
  • - Company Strategy
  • - Mergers, Acquisitions and Divestitures
  • - Key Agreements
  • - R&D Strategy
  • - Production
  • - Employees
  • - Product Performance Forecasts
  • - Pipeline Analysis
  • - Discontinued R&D Projects
  • - Conclusions

Some of the Companies Mentioned in this Report:

  • Anthera Pharmaceuticals Inc
  • Array BioPharma Inc
  • AstraZeneca
  • Biovitrum AB
  • Boehringer Ingelheim Pharma KG
  • Genmab A/S
  • GlaxoSmithKline
  • Human Genome Sciences Inc (HGS)
  • ImmunoGen
  • Infinity Pharmaceuticals Incorporated
  • InteKrin Therapeutics
  • InterMune Inc
  • Isis Pharmaceuticals Inc
  • Johnson & Johnson
  • Kirin Brewery Co Ltd/Kirin-Amgen
  • Kyowa Hakko Kirin
  • Medarex Inc
  • MedGenesis Therapeutix
  • Memory Pharmaceuticals
  • NPS Pharmaceuticals Inc
  • Roche
  • Takeda
  • Three Rivers Pharmaceuticals
  • UCB
  • Wyeth (Pfizer)
  • ZymoGenetics Inc

For more information visit

Source: Espicom Business Intelligence Ltd


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United Kingdom  United States  Europe  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical